Efficacy of adalimumab for the management of Inflammatory Bowel Disease in the Clinical Setting

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 7, 2009, Pages 1252-1257

  Trinder, Matthew W ^b   Lawrance, Ian C ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Adalimumab; Crohn's disease; Inflammatory bowel disease; Therapy; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CIPROFLOXACIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; STEROID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DISEASE CONTROL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FISTULA; GASTROINTESTINAL REFLUX; HERPES SIMPLEX; HUMAN; LOADING DRUG DOSE; MALE; NAUSEA; PRIORITY JOURNAL; RASH; REMISSION; STEVENS JOHNSON SYNDROME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 68749118728     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05786.x     Document Type: Article

References (22)

1. Rutgeerts P, Assche G, Vermeire S. Anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004 126 : 1593 610.
2. Targan S, Hanauer S, Deventer SV, Mayer L, Present D, Braakman T. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 1997 337 : 1029 35.
3. Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 9.
4. Mortimore M, Gibson P, Selby W, Radford-Smith G, Florin T. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? Intern. Med. J. 2001 31 : 146 50.
5. Pearce C, Lawrance I. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2007 22 : 1671 7.
6. Schattenkirchner M, Kruger K, Sander O, Rau R. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis-results of a phase I study. Arthritis Rheum. 1998 41 : S57.
7. Heijde D, Kivitz A, Schiff M, Sieper J. Efficacy and saftey of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum. 2006 54 : 2136 46.
8. Mease P, Gladman D, Ritchlin C, Ruderman E, Steinfeld S. Adalimumab for the treatment of patients with moderately to severe active psoriatic arthritis. Arthritis Rheum. 2005 52 : 3279 89.
9. Furst D, Schiff M, Fleischmann R, Strand V. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 2003 30 : 2563 71.
10. Hanauer S, Sandborn W, Rutgeerts P, Fedorak R. Human anti-tumour necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 130 : 323 33.
11. Colombel J, Sandborn W, Rutgreerts P, Enns R. Adalimumab for maintenance of clinical response and remission in patients with Crohn's Disease: the CHARM Trial. Gastroenterology 2007 132 : 52 65.
12. Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J. Clin. Lab. Immunol. 1995 46 : 111 23.
13. Rutgeerts P, Feagan B, Olson A, Johanns J, Travers S, Present D. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005 353 : 2462 76.
14. Willert R, Lawrance I. The use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory Ulcerative colitis. World J. Gastroenterol. 2008 14 : 2544 9.
15. Silverberg M, Satsangi J, Ahmad T, Arnott I, Bernstein C, Brant S. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 2005 19 : 5 36.
16. Lennard-Jones J. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. 1989 170 : 2 6.
17. Best W, Becktel J, Singleton J, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976 70 : 439 44.
18. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989 298 : 82 6.
19. Rutgeerts P, Sandborn W, Enns R, Hanauer S. Adalimumab rapidly induces clinical response and remission in patients with moderate to severe Crohn's disease who had secondary failure to infliximab therapy: results of the GAIN study. Gut 2006 55 : 20.
20. Konstantinos A, Papadakis M, Omid A, Shaye M. Saftey and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am. J. Gastroenterol. 2005 100 : 75 9.
21. Peryrin-Biroulet L, Laclotte C, Roblin X, Bigard M. Adalimumab indcution therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J. Gastroenterl. 2007 13 : 2328 32.
22. Beuthien W, Mellinghoff H, Kempis J. Skin reaction to adalimumab. Arthritis Rheum. 2004 50 : 1690 2.